GlassScriptPhysician profile
Kristin Pena
NPI 1861554552
$6,630.48
in general payments reported to CMS, 2019-2025
33 companies · $634 in 2025
The $634 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,229 · 2020: $412 · 2021: $771 · 2022: $1,197 · 2023: $1,197 · 2024: $1,191 · 2025: $634.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,925 · Education: $97.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,924.64 |
| Education | $97.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,168.94 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Gilead Sciences, INC. | $978.18 | 2020-2025 | Epclusa |
| Abbvie INC. | $954.80 | 2019-2025 | |
| Mannkind Corporation | $370.04 | 2022-2024 | Afrezza |
| Nevro Corp. | $278.85 | 2023-2024 | Senza |
| Astrazeneca Pharmaceuticals LP | $273.11 | 2019-2024 | Breztri, Airsupra |
| Glaxosmithkline, LLC. | $249.82 | 2019-2025 | Arexvy, Shingrix |
| Genzyme Corporation | $215.72 | 2024 | |
| Astellas Pharma US INC | $200.44 | 2024 | Veozah |
| Inspire Medical Systems, INC. | $192.15 | 2021-2024 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $159.65 | 2019-2025 | Jardiance |
| Neurocrine Biosciences, INC. | $152.17 | 2019 | |
| Silk Road Medical, INC. | $150.00 | 2022 | |
| Amgen INC. | $129.30 | 2022 | |
| Amarin Pharma, INC. | $125.00 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $115.78 | 2019 | |
| Idorsia Pharmaceuticals US INC | $112.12 | 2023 | Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $111.15 | 2022 | |
| Abbott Laboratories | $109.76 | 2022 | |
| Boston Scientific Corporation | $106.40 | 2019 | |
| Vertiflex, INC. | $87.21 | 2019 | |
| Endogastric Solutions, INC | $67.21 | 2023 | Esophyx |
| Organon LLC | $59.76 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $41.54 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $37.59 | 2024 | Dupixent |
| Pfizer INC. | $35.19 | 2021 | |
| Verrica Pharmaceuticals INC. | $26.41 | 2024 | Ycanth |
| Merck Sharp & Dohme LLC | $25.12 | 2019 | |
| Exact Sciences Corporation | $22.53 | 2025 | The Cologuard Plus Collection Kit |
| Hologic Sales and Service, LLC | $21.88 | 2021 | |
| Arbor Pharmaceuticals, INC. | $20.42 | 2021 | |
| Cranial Technologies, INC | $20.27 | 2023 | Doc Band |
| Sanofi Pasteur INC. | $11.97 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristin Pena listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.